Compare Halliburton Company (HAL) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Halliburton Company vs Medpace Holdings Inc — how do they compare? Halliburton Company trades at $32.44 (market cap $27.14B), while Medpace Holdings Inc trades at $602 (market cap $16.82B). The key difference: Halliburton Company is the larger of the two by market cap, and Halliburton Company pays a 2.09% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Halliburton Company for 89 Days and Medpace Holdings Inc for 14 Days on average.
| HAL | MEDP | |
|---|---|---|
Market Cap | $27.14B | $16.82B |
Volume | 11,258,156 | 223,093 |
Sector | Energy | Health |
52-Week High | $42.98 | $630.19 |
52-Week Low | $21.82 | $393.42 |
Typical Hold Time | 89 Days | 14 Days |
Enterprise Value | $33.29B | $16.44B |
Dividend Yield | 2.09% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Halliburton (HAL) trades at $31.75, down 2.96% on the day, with technical indicators showing bearish momentum. The stock has demonstrated consistent earnings beats in recent quarters and maintains solid profitability metrics including 7.16% net margin and 14.89% ROE. Recent developments include expansion into Venezuela through partnerships with Eneva and WESCA, along with a major contract win for Cyprus' Cronos gas project, positioning the company for international growth opportunities.
Despite near-term technical weakness, Halliburton presents value with a 16.62 P/E ratio and strong analyst support (73% buy ratings) targeting $43.11 consensus. Risks include oil price volatility and execution challenges in new international markets, but the company's diversified service portfolio and improving cash flow trends support long-term growth prospects in the energy services sector.
MEDP trades at $604.25, up 0.22% with neutral technical signals and strong fundamental performance. The stock shows robust profitability with 17.67% net income margin and consistent earnings beats in recent quarters. Recent news highlights institutional activity including CEO stock sales and upcoming Q3 2026 earnings report on October 21, 2026. Technical indicators show mixed signals with RSI neutral and ADX bullish, while support sits at $589 and resistance at $629.
MEDP presents a mixed outlook with strong fundamentals offset by high valuations and insider selling. The 21% buy rating from analysts suggests cautious optimism, with $620.44 price target offering 2.7% upside. Key risks include elevated P/E ratio of 35.5 and recent CEO stock sales totaling over $44 million in September 2026. Positive cash flow projection for 2026 supports growth potential despite current net outflow.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Halliburton Company
Halliburton is one of the three largest oilfield service firms in the world, offering superior expertise in a number of business lines, including completion fluids, wireline services, cementing, and countless others. It's the number one pressure pumper in North America, and has been a leading innovator in hydraulic fracturing over the last two decades.
Read more on HAL →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
